 |
|
|
| |
C-EDGE COINFECTION: PHASE 3 STUDY OF GRAZOPREVIR/ELBASVIR IN PATIENTS WITH HCV/HIV
|
| |
| |
.....from Jules: of note, 95% SVR rate, no difference in SVR between whites & blacks (see Figure 3), no difference between those with or without cirrhosis
Reported by Jules Levin
EASL 2015 Vienna, Austria April 22-26
Jürgen K. Rockstroh1, Mark Nelson2, Christine Katlama3, Jay Lalezari4, Josep Mallolas5, Mark Bloch6, Gail Matthews7, Michael S. Saag8, Philippe Zamor9, Chloe Orkin10, Jacqueline Gress11, Melissa Shaughnessy11, Stephanie Klopfer11, Janice Wahl11, Bach-Yen Nguyen11, Eliav Barr11, Heather L. Platt11, Michael Robertson11, Mark Sulkowski12
1Bonn University Hospital, Bonn, Germany; 2Chelsea and Westminster Hospital, London, UK; 3Université Pierre et Marie Curie, Paris VI and Hôpital Pitié-Salpêtrière, Paris, France; 4Quest Clinical Research, San Francisco, CA, USA; 5Hospital Clinic-University of Barcelona, Spain; 6Holdsworth House Medical Practice, Darlinghurst NSW, Australia; 7St Vincent's Hospital, Sydney, NSW, Australia; 8University of Alabama at Birmingham, Birmingham, Alabama, USA; 9Carolinas Medical Center, Charlotte, NC, USA; 10Royal London hospital , Bart's Health NHS Trust, London, UK; 11Merck & Co. Inc., Kenilworth, NJ, USA; 12Johns Hopkins University School of Medicine, Baltimore, MD, USA
|
| |
|
|
|
|
|
